Trading of Hansa Medical's share initiated on Nasdaq Stockholm main market

Hansa Medical AB (publ) has today, November 2, 2015, started the trading of its shares (STO:HMED) on the main market of Nasdaq Stockholm.

“We are pleased to welcome Hansa Medical to Nasdaq Stockholm's main market. Hansa Medical joins our growing healthcare sector and we look forward to supporting them with the increased investor visibility that comes with a main market listing”, said Adam Kostyál, senior vice president and head of European listings at Nasdaq.

“In 2015, we have made significant progress in our prioritized clinical development programs. Our vision is to build a sustainable biopharmaceutical company with pharmaceuticals that significantly improve health outcomes in patients. We are getting the cornerstones in place for future growth. The upgrade to Nasdaq Stockholm’s main market has the potential to make Hansa Medical even more attractive to existing and new investors”, said Göran Arvidson, President and CEO of Hansa Medical AB.

The information in this press release is disclosed pursuant to the Securities Markets Act or the Financial Instruments Trading Act. The information was released for public disclosure on November 2, 2015 at 10.00 CET.

For further information, please contact:
Hansa Medical AB
Göran Arvidson, CEO
Mobile: 46 70-390 85 30
E-mail: goran.arvidson@hansamedical.com
www.hansamedical.com

About Hansa Medical AB
Hansa Medical is a biopharmaceutical company focused on novel immunomodulatory enzymes. Lead project IdeS is an antibody-degrading enzyme in clinical development, with potential use in transplantation and rare autoimmune diseases. Other projects include HBP (a market introduced diagnostic marker for severe sepsis) and EndoS (an antibody-modulating bacterial enzyme in pre-clinical development). The company is based in Lund, Sweden. Hansa Medical's share (STO:HMED) is listed on Nasdaq Stockholm.

Tags:

About Us

Hansa Medical is a biopharmaceutical company focused on novel immunomodulatory enzymes. Lead project IdeS is an antibody-degrading enzyme in clinical development, with potential use in transplantation and rare autoimmune diseases. Other projects include HBP (a market introduced diagnostic marker for severe sepsis) and EndoS (an antibody-modulating bacterial enzyme in pre-clinical development). The company is based in Lund, Sweden. Hansa Medical's share (HMED) is listed on Nasdaq First North in Stockholm with Remium Nordic AB as Certified Adviser.